Skip to main content

Table 1 Hormonal levels during the course of GnRH analogue pretreatment

From: Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study

Groups

n

FSH (mIU/ml)

LH (mIU/ml)

E2 (pg/ml)

1st day

3rd day

5th day

8th day

1st day

3rd day

5th day

8th day

1st day

3rd day

5th day

8th day

Control

12

2.45±0.13

2.43±0.08

2.32±0.06

2.45±0.12

2.77±0.18

2.83±0.19

2.84±0.11

2.90±0.21

252.98±10.29

242.00±12.96

256.60±11.75

246.03±2.80

CDDP

12

2.51±0.16

2.49±0.09

2.41±0.05

2.44±0.14

2.75±0.16

2.83±0.20

2.66±0.32

2.89±0.17

257.71±13.28

252.60±13.90

250.59±11.07

250.98±4.09

GnRHa

12

2.47±0.08

2.71±0.10

2.21±0.07

2.33±0.11

2.87±0.18

3.93±0.13a

2.81±0.27

2.89±0.11

250.34±13.01

265.42±13.49

197.10±13.43

159.63±2.52ab

GnRHant

12

2.33±0.07

2.22±0.11

2.01±0.07

2.14±0.14

2.70±0.12

2.56±0.06

2.42±0.14

2.62±0.08

252.83±11.75

153.04±12.37a

179.87±13.83

151.87±3.43ab

Combination (lng)

12

2.52±0.13

2.29±0.10

2.44±0.05

2.48±0.07

2.96±0.20

2.74±0.05

2.73±0.13

2.64±0.30

247.65±2.80

171.95±7.20a

185.10±13.86

96.57±5.79a

Combination (sht)

12

2.64±0.09

2.33±0.10

2.24±0.25

2.30±0.16

2.88±0.12

2.53±0.17

2.86±0.21

2.75±0.07

260.86±19.57

163.60±17.4a

214.63±11.77

142.21±8.34ab

  1. aP<0.01 vs. control group; bP<0.01 vs. combination (lng) group.
  2. Data are expressed as the mean ± standard error.